OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE-EXPRESSION

被引:82
作者
GHOSH, MK
COHEN, JS
机构
[1] Cancer Pharmacology Section, Pharmacology Department, Georgetown University Medical School, Washington
来源
PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY | 1992年 / 42卷
关键词
D O I
10.1016/S0079-6603(08)60574-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A new type of drug molecule synthesized with a specific base sequence designed to interact with a target nucleic acid containing the complementary sequence are being developed. In the earliest and most developed example of this approach, oligodeoxynucleotides and their analogs have been applied as antisense inhibitors of gene expression to bring about translation arrest. This chapter discusses the use of antisense oligodeoxynucleotides as a therapeutic approach. Once this approach is recognized in principle, other examples can be seen to fit a pattern, such as the use of oligodeoxynucleotides to form a triple-strand helix with duplex DNA. However, with a different base triplet code to arrest transcription, the opening of duplex DNA is not considered facile enough to allow the access of an oligo to interact with one of the strands. The development of synthetic oligoribonucleotides as ribozymes is another example in which the information for the selectivity is encoded in the portions of the oligomer flanking the catalytic site. Another example is the use of oligodeoxynucleotides to bind to protein sites that recognize specific sequences of bases, thus, inhibiting polymerase action or bringing about transcription arrest by sequestering specific transcription cofactors. Thus, a new area of pharmacology is developing that is differentiated by the purposeful inclusion of information in the form of nucleic-acid bases in a putative oligonucleotide drug molecule. © 1992, Academic Press Inc.
引用
收藏
页码:79 / 126
页数:48
相关论文
共 220 条
[1]   PHARMACOKINETICS, BIODISTRIBUTION, AND STABILITY OF OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES IN MICE [J].
AGRAWAL, S ;
TEMSAMANI, J ;
TANG, JY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (17) :7595-7599
[2]   SITE-SPECIFIC EXCISION FROM RNA BY RNASE-H AND MIXED-PHOSPHATE-BACKBONE OLIGODEOXYNUCLEOTIDES [J].
AGRAWAL, S ;
MAYRAND, SH ;
ZAMECNIK, PC ;
PEDERSON, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (04) :1401-1405
[3]   OLIGODEOXYNUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHOROTHIOATES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS [J].
AGRAWAL, S ;
GOODCHILD, J ;
CIVEIRA, MP ;
THORNTON, AH ;
SARIN, PS ;
ZAMECNIK, PC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (19) :7079-7083
[4]   SITE SPECIFIC FUNCTIONALIZATION OF OLIGONUCLEOTIDES FOR ATTACHING 2 DIFFERENT REPORTER GROUPS [J].
AGRAWAL, S ;
ZAMECNIK, PC .
NUCLEIC ACIDS RESEARCH, 1990, 18 (18) :5419-5423
[5]   INHIBITION OF VESICULAR STOMATITIS-VIRUS PROTEIN-SYNTHESIS AND INFECTION BY SEQUENCE-SPECIFIC OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATES [J].
AGRIS, CH ;
BLAKE, KR ;
MILLER, PS ;
REDDY, MP ;
TSO, POP .
BIOCHEMISTRY, 1986, 25 (20) :6268-6275
[6]   CONFIGURATION OF BETA-GLOBIN MESSENGER-RNA IN RABBIT RETICULOCYTES - IDENTIFICATION OF SITES EXPOSED TO ENDOGENOUS AND EXOGENOUS NUCLEASES [J].
ALBRECHT, G ;
KROWCZYNSKA, A ;
BRAWERMAN, G .
JOURNAL OF MOLECULAR BIOLOGY, 1984, 178 (04) :881-896
[7]   ALPHA-OLIGODEOXYNUCLEOTIDE STABILITY IN SERUM, SUBCELLULAR EXTRACTS AND CULTURE MEDIA [J].
BACON, TA ;
MORVAN, F ;
RAYNER, B ;
IMBACH, JL ;
WICKSTROM, E .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1988, 16 (04) :311-318
[8]  
BARTLETT PA, 1982, J BIOL CHEM, V257, P8879
[9]   SYNTHESIS AND CHARACTERIZATION OF NUCLEOSIDE PEPTIDES - TOWARD CHEMICAL RIBONUCLEASES .1. [J].
BASHKIN, JK ;
GARD, JK ;
MODAK, AS .
JOURNAL OF ORGANIC CHEMISTRY, 1990, 55 (17) :5125-5132
[10]   ANTIVIRAL ACTIVITY IN L1210 CELLS OF LIPOSOME-ENCAPSULATED (2'-5')OLIGO(ADENYLATE) ANALOGS [J].
BAYARD, B ;
LESERMAN, LD ;
BISBAL, C ;
LEBLEU, B .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1985, 151 (02) :319-325